Metabolism of OR-1896, a metabolite of levosimendan, in rats and humans

Xenobiotica

Volumn 38, Issue 2, 2008, Pages 156-170

  Koskinen, M ^a,d   Puttonen, J ^a,b,c   Pykalainen M ^a   Vuorela, A ^a   Lotta, T ^a  

^a ORION CORPORATION   (Finland)

^b IQVIA   (United States)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d University of Kuopio ^*  (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DRUG METABOLITE; GLUCURONIDE; LEVOSIMENDAN; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; OR 1855; SULFATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DEACETYLATION; DRUG CONJUGATION; DRUG DETERMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG SULFATION; DRUG TRANSFORMATION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NONHUMAN; RAT; URINARY EXCRETION;

ACETAMIDES; ADULT; ANIMALS; CARDIOTONIC AGENTS; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 38149022672     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701744658     Document Type: Article

References (14)

1. Antila S, Huuskonen H, Nevalainen T, Kanerva H, Vanninen P, Lehtonen L. 1999. Site dependent bioavailability and metabolism of levosimendan in dogs. European Journal of Pharmaceutical Science 9:85-91.
2. Antila S, Kivikko M, Lehtonen L, Eha J, Heikkilä A, Pohjanjousi P, Pentikäinen PJ. 2004. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. British Journal of Clinical Pharmacology 57:412-415.
3. Babu SR, Lakshmi VM, Huang GP, Zenser TV, Davis BB. 1996. Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites. pH stability and synthesis by human and dog liver. Biochemistry and Pharmacology 51:1679-1685.
4. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola V-P, Mitrovic V, Abdalla M, Sandell E-P, Lehtonen L. 2002. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 360:196-202.
5. Innes CA, Wagstaff AJ. 2003. Levosimendan. A review of its use in the management of acute decompensated heart failure. Drugs 63:2651-2671.
6. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. 2002a. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. International Journal of Clinical Pharmacology and Therapy 40:465-471.
7. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. 2002b. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. Journal of Clinical Pharmacology 42:43-51.
8. Kivikko M, Lehtonen L, Colucci WS, on Behalf of the Study Investigators. 2003. Sustained hemodynamic effects of intravenous levosimendan. Circulation 107:81-86.
9. Kristof E, Sziketi G, Papp Z, Bodi A, Facsko A, Kovacs L, Papp JG, Kranias EG, Edes I. 1998. Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration and left ventricular function. Annals of the New York Academy of Sciences 853:316-319.
10. Puttonen J, Laine T, Ramela M, Häkkinen S, Zhang W, Pradhan R, Pentikäinen P, Koskinen M. 2007. Pharmacokinetics and excretion balance of OR-1896, a metabolite of levosimendan, in healthy men. European Journal of Pharmaceutical Science 32:271-277.
11. Sandell E-P, Häyhä M, Antila S, Heikkinen P, Ottoila P, Lehtonen L, Pentikäinen PJ. 1995. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. Journal of Cardiovascular Pharmacology 26(Suppl. 1):S57-S62.
12. Sundberg S, Antila S, Scheinin H, Häyhä M, Virtanen M, Lehtonen L. 1998. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. International Journal of Clinical Pharmacology and Therapy 36:629-635.
13. Takahashi R, Talukder MAH, Endoh M. 2000a. Effects of OR-1896, an active metabolite of levosimendan on contractile force and aequorin light transients in intact rabbit ventricular myocardium. Journal of Cardiovascular Pharmacology 36:118-125.
14. Takahashi R, Talukder MAH, Endoh M. 2000b. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. European Journal of Pharmacology 400:103-112.